Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.

The Biochemical journal - 23 Oct 2009

Nichols R Jeremy, Dzamko Nicolas, Hutti Jessica E, Cantley Lewis C, Deak Maria, Moran Jennifer, Bamborough Paul, Reith Alastair D, Alessi Dario R

Abstract excerpt

The LRRK2 (leucine-rich repeat protein kinase-2) is mutated in a significant number of Parkinson's disease patients, but little is known about its regulation and function. A common mutation changing Gly2019 to serine enhances catalytic activity, suggesting that small-molecule inhibitors might have utility in treating Parkinson's disease. We employed various approaches to explore the substrate-specificity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Enzyme Activation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Parkinson Disease

Share to Protein Structure, Secondary

Share to Pyridines

Share to rho-Associated Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 19740074
DOI: 10.1042/BJ20091035
PMCID: PMC3759966

Genes

ROCK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.PMID 19740074Read ↗

Targeting LRRK2 in Parkinson's disease: an update on recent developments.Semantic proximity Read ↗

LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.Semantic proximity Read ↗

Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.Semantic proximity Read ↗

Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.Semantic proximity Read ↗

The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.Semantic proximity Read ↗

Role of LRRK2 in physiological activities, diseases, and therapy.Semantic proximity Read ↗

LRRK2 in Parkinson's disease: biochemical functions.Semantic proximity Read ↗

Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease ModelsSemantic proximity Read ↗

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s diseaseSemantic proximity Read ↗

Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.Semantic proximity Read ↗

Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.